| First Author | Ahmad F | Year | 2014 |
| Journal | J Am Coll Cardiol | Volume | 64 |
| Issue | 7 | Pages | 696-706 |
| PubMed ID | 25125302 | Mgi Jnum | J:272204 |
| Mgi Id | MGI:6281244 | Doi | 10.1016/j.jacc.2014.04.068 |
| Citation | Ahmad F, et al. (2014) Cardiomyocyte-specific deletion of Gsk3alpha mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol 64(7):696-706 |
| abstractText | BACKGROUND: Injury due to myocardial infarction (MI) is largely irreversible. Once an infarct has occurred, the clinical goal becomes limiting remodeling, preserving left ventricular function, and preventing heart failure. Although traditional approaches (e.g., beta-blockers) partially preserve left ventricular function, novel strategies are needed to limit ventricular remodeling post-MI. OBJECTIVES: The aim of this study was to determine the role of glycogen synthase kinase-3alpha (GSK-3alpha) in post-MI remodeling. METHODS: Mice with cardiomyocyte-specific conditional deletion of Gsk3alpha and littermate controls underwent sham or MI surgery. Heart function was assessed using serial M-mode echocardiography. RESULTS: Gsk3alpha deletion in the heart markedly limits remodeling and preserves left ventricular function post-MI. This is due at least in part to dramatic thinning and expansion of the scar in the control hearts, which was less in the heart of knockout (KO) mice. In contrast, the border zone in the KO mice demonstrated a much thicker scar, and there were more viable cardiomyocytes within the scar/border zone. This was associated with less apoptosis and more proliferation of cardiomyocytes in the KO mice. Mechanistically, reduced apoptosis was due, at least in part, to a marked decrease in the Bax/Bcl-2 ratio, and increased cardiomyocyte proliferation was mediated through cyclin E1 and E2F-1 in the hearts of the KO mice. CONCLUSIONS: Taken together, these findings show that reducing GSK-3alpha expression in cardiomyocytes limits ventricular remodeling and preserves cardiac function post-MI. Specifically targeting GSK-3alpha could be a novel strategy to limit adverse remodeling and heart failure. |
